Renee M. McKay

Renee M. McKay

Auto-generated profile, based on publicly available information

Renee M. McKay

Department of Dermatology, University of Virginia School of Medicine, Charlottesville, Virginia, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
BSBandarigoda N. Somatilaka
Bandarigoda N. Somatilaka
ASAli Sadek
Ali Sadek
RMRenee M. McKay
Renee M. McKay
LLLu Q. Le
Lu Q. Le

23 January 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
JMJuan Mo
Juan Mo
SMStefanie L. Moye
Stefanie L. Moye
RMRenee M. McKay
Renee M. McKay
LLLu Q. Le
Lu Q. Le

3 June 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JVJoseph Vento
Joseph Vento
AMAditi Mulgaonkar
Aditi Mulgaonkar
LWLayton Woolford
Layton Woolford
KNKien Nham
Kien Nham
ACAlana Christie
Alana Christie
JBJames Brugarolas
James Brugarolas
Background Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. Most studies of PD-L1 are limited by evaluation in primary rather than metastatic sites, and in biopsy samples, which may not be representative. These limitations may be overcome with immuno–positron emission tomography (iPET), an emerging tool allowing the detection of cell surface proteins with radiolabeled antibodies. Here, we report iPET studies of PD-L1 in a preclinical tumorgraft model of clear cell RCC (ccRCC) from a patient who had a favorable response to anti-PD-1 therapy. Case presentation A 49-year-old man underwent a cytoreductive nephrectomy in 2017 of a right kidney tumor invading into the adrenal gland that was metastatic to the lungs and a rib. Histological analyses revealed a ccRCC of ISUP grade 4 with extensive sarcomatoid features. IMDC risk group was poor. Within two hours of surgery, a tumor sample was implanted orthotopically into NOD/SCID mice. Consistent with an aggressive tumor, a renal mass was detected 18 days post-implantation. Histologically, the tumorgraft showed sarcomatoid differentiation and high levels of PD-L1, similar to the patient’s tumor. PD-L1 was evaluated in subsequently transplanted mice using iPET and the results were compared to control mice implanted with a PD-L1-negative tumor. We labeled atezolizumab, an anti-PD-L1 antibody with a mutant Fc, with zirconium-89. iPET revealed significantly higher 89Zr-atezolizumab uptake in index than control tumorgrafts. The patient was treated with high-dose IL2 initially, and subsequently with pazopanib, with rapidly progressive disease, but had a durable response with nivolumab. Conclusions To our knowledge, this is the first report of non-invasive detection of PD-L1 in renal cancer using molecular imaging. This study supports clinical evaluation of iPET to identify RCC patients with tumors deploying the PD-L1 checkpoint pathway who may be most likely to benefit from PD-1/PD-L1 disrupting drugs.

3 August 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
CJChunhui Jiang
Chunhui Jiang
RMRenee M. McKay
Renee M. McKay
LLLu Q. Le
Lu Q. Le

15 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CJChunhui Jiang
Chunhui Jiang
AKAshwani Kumar
Ashwani Kumar
ZYZe Yu
Ze Yu
TSTracey Shipman
Tracey Shipman
YWYong Wang
Yong Wang
LLLu Q. Le
Lu Q. Le
Neurofibromatosis type 1 (NF1) is one of the most common tumor-predisposing genetic disorders. Neurofibromas are NF1-associated benign tumors. A hallmark feature of neurofibromas is an abundant collagen-rich extracellular matrix (ECM) that constitutes more than 50% of the tumor dry weight. However, little is known about the mechanism underlying ECM deposition during neurofibroma development and treatment response. We performed a systematic investigation of ECM enrichment during plexiform neurofibroma (pNF) development and identified basement membrane (BM) proteins, rather than major collagen isoforms, as the most upregulated ECM component. Following MEK inhibitor treatment, the ECM profile displayed an overall downregulation signature, suggesting ECM reduction as a therapeutic benefit of MEK inhibition. Through these proteomic studies, TGF-β1 signaling was identified as playing a role in ECM dynamics. Indeed, TGF-β1 overexpression promoted pNF progression in vivo. Furthermore, by integrating single-cell RNA sequencing, we found that immune cells including macrophages and T cells produce TGF-β1 to induce Schwann cells to produce and deposit BM proteins for ECM remodeling. Following Nf1 loss, neoplastic Schwann cells further increased BM protein deposition in response to TGF-β1. Our data delineate the regulation governing ECM dynamics in pNF and suggest that BM proteins could serve as biomarkers for disease diagnosis and treatment response.

16 June 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CJChunhui Jiang
Chunhui Jiang
RMRenée M. McKay
Renée M. McKay
SLSang Lee
Sang Lee
CRCarlos Guillermo Romo
Carlos Guillermo Romo
JBJaishri O. Blakeley
Jaishri O. Blakeley
LLLu Q. Le
Lu Q. Le